FOR IMMEDIATE RELEASE
Xcelthera Inc Secures First U.S.
Xcelthera
Inc (http://www.xcelthera.com), a major innovator in the stem cell research
market and one of the first U.S. companies formed for
clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs, and its
joint research partner San Diego Regenerative Medicine Institute announced
today that the U.S. Patent and Trademark Office (USPTO) has granted Patent No. 8,716,017 entitled “Technologies,
Methods, and Products of Small Molecule-Directed Tissue and Organ Regeneration
from Human Pluripotent Stem Cells”. This newly-issued patent is the first among
a portfolio of intellectual property of Xcelthera Inc covering PluriXcel human
stem cell technology platform for large-scale
production of high quality clinical-grade pluripotent human ES cell lines and
their functional human neuronal and heart muscle cell therapy products.
Neurodegenerative
and heart diseases are major health problems and cost the worldwide healthcare
system more than $500 billion annually. The limited capacity of these two cell systems -- neurons
and cardiomyocytes -- for self-repair makes them suitable for stem cell-based
neuronal and heart therapies. Nevertheless, to date, the existing
markets lack a clinically-suitable human neuronal cell source or cardiomyocyte source
with adequate regenerative potential, which has been the major setback in
developing safe and effective cell-based therapies for neurodegenerative and heart diseases. Xcelthera proprietary PluriXcel technology allows efficient derivation
of clinical-grade human ES cell lines and direct
conversion of such pluripotent human ES cells by small molecule
induction into a large
commercial scale of high quality human neuronal or heart muscle cells, which constitutes clinically representative progress in
both human neuronal and cardiac therapeutic products for treating neurodegenerative
and heart diseases.
PluriXcel
technology of Xcelthera Inc is milestone advancement in stem cell research,
offering currently the only available human cell therapy products with the
pharmacological capacity to regenerate human neurons and contractile heart
muscles that allow restitution of function of the central
nervous system (CNS) and heart in the clinic. Through
technology license agreement with San Diego Regenerative Medicine Institute,
Xcelthera Inc has become the first in the world to hold
the proprietary breakthrough technology for large-scale production of high
quality clinical-grade pluripotent human ES cell lines and their functional
human neuronal and heart cell therapy products for commercial and
therapeutic uses.
As
neurodegenerative and heart diseases incur exorbitant costs on the healthcare
system worldwide, there is a strong focus on providing newer and more efficient
solutions for these therapeutic needs. Millions of people are pinning their
hopes on stem cell research. PluriXcel technology platform of Xcelthera Inc is
incomparable, providing life
scientists and clinicians with novel and effective resources to address major
health concerns. Such
breakthrough stem cell technology has presented human ES cell therapy
derivatives as a powerful pharmacologic agent of cellular entity for a wide range of incurable or hitherto untreatable
neurodegenerative and heart diseases. Introduction of medical innovations and
new business opportunities based on PluriXcel technology will shape the future
of medicine by providing pluripotent human ES cell-based technology for human
tissue and function restoration, and bringing new therapeutics into the market.
About Xcelthera Inc.
Xcelthera INC (http://www.xcelthera.com)
is a new biopharmaceutical company moving towards clinical development stage of
novel and most advanced stem cell therapy for a wide range of neurological and
cardiovascular diseases with leading technology and ground-breaking medical
innovation in cell-based regenerative medicine. The Company was recently incorporated in the
state of California to commercialize the technologies
and products developed, in part, with supports by government grants to the
founder, by San Diego Regenerative Medicine
Institute (SDRMI), an non-profit 501C3 tax-exempt status independent biomedical
research institute that is interested in licensing its PATENT RIGHTS in a manner
that will benefit the public by facilitating the distribution of useful
products and the utilization of new processes, but is without capacity to
commercially develop, manufacture, and distribute any such products or
processes. Xcelthera is a
major innovator in the stem cell research market and one of the first companies formed for clinical applications of human embryonic stem cell (human ES
cell) therapeutic utility for unmet medical needs. The Company is the first to hold the proprietary breakthrough
technology for large-scale production of high quality clinical-grade pluripotent
human ES cell lines and their functional human neuronal and heart muscle cell
therapy products for commercial and therapeutic uses. The Company owns or has exclusive
rights in a portfolio of intellectual property or license rights related to its
novel PluriXcel human stem cell technology platforms and Xcel prototypes of human
stem cell therapy products. The inception of
Xcelthera is driven by the urgent need for clinical translation of human ES
cell research discoveries and innovations to address unmet medical challenges
in major health problems. Xcelthera breakthrough
developments in human ES cell research dramatically increase the overall
turnover of investments in biomedical sciences to optimal treatment options for
a wide range of human diseases. The overall
strategy of the Company is to use cutting-edge human stem cell technology to
develop clinical-grade functional human neural and cardiac cell therapy
products from pluripotent human ES cells as
cellular medicine or cellular drugs to provide the next generation of
cell-based therapeutic solutions for unmet medical needs in world-wide major
health problems. The Company is currently offering Series A
Convertible Preferred Stock to accredited investors through equity crowdfunding
to raise fund for its pre-IPO business operation
and filing confidential IPO as an emerging growth company according to the JOBS
Act to create a public market for its common stock
and to facilitate its future access to the public equity market and growth of
the Company.
Visit Xcelthera Inc. at http://www.xcelthera.com.
For more information or investment opportunity about
Xcelthera series A round, please contact:
Xuejun
H Parsons, PhD, Chief Executive Officer
Xcelthera Inc.
Xcelthera Inc.
http://www.xcelthera.com
888-706-5396 or 858-243-2046
investors@xcelthera.com or parsons@xcelthera.com
888-706-5396 or 858-243-2046
investors@xcelthera.com or parsons@xcelthera.com
About San Diego
San Diego
Regenerative Medicine Institute (http://www.sdrmi.org),
a nonprofit independent biomedical research institute with 501C3 IRS tax-exempt
status, was founded in 2010 to facilitate the transition of human stem cell
research towards stem cell therapy to provide the next generation of cell-based
therapeutic solutions for unmet medical challenges in world-wide major health
problems. SDRMI is committed to the leading position in pluripotent human ES
cell research and cell-based regenerative medicine by developing groundbreaking
human ES cell technology platforms and innovative cell-based regenerative
medicine approaches.
No comments:
Post a Comment